No matches
Pulmonology

Spanish: How Can FeNO Measurement Improve Severe Asthma Management?

Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma in Spanish.
Miguel Lanz
MD, FAAAAI
Miguel Lanz

Related resources

Type 2 Inflammation Underpins Pediatric Severe Asthma

Type 2 Inflammation Underpins Pediatric Severe Asthma

Infographic
ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Podcast
Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

videoanimation
How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

videoanimation
EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

expert video
EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

expert video
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

expert video
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Podcast
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
COPD and Asthma: What's the Difference and Is There a Link?

COPD and Asthma: What's the Difference and Is There a Link?

interactivity
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

videoanimation
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
On-Treatment Clinical Remission in Asthma Patients Case Tool

On-Treatment Clinical Remission in Asthma Patients Case Tool

interactivity
Pediatric Asthma Patient Case Tool: Ash

Pediatric Asthma Patient Case Tool: Ash

interactivity
The Cycle of Inflammation in Adult Asthma

The Cycle of Inflammation in Adult Asthma

interactivity
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Infographic
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

expert video
ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

expert video
ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

Podcast
Blood Eosinophils: A Biomarker in COPD

Blood Eosinophils: A Biomarker in COPD

Infographic
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

expert video
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

expert video
ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

expert video
Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

videoanimation
Adult Asthma Interactive Patient Cases

Adult Asthma Interactive Patient Cases

interactivity
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

expert video
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

expert video
ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

expert video
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

expert video
ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
How Can FeNO Measurement Improve Severe Asthma Management?

How Can FeNO Measurement Improve Severe Asthma Management?

expert video

Learning objectives

  • Identify how type 2 inflammation leads to an increase in exhaled nitric oxide in severe asthma patients
  • Understand the clinical utility of FeNO as a diagnostic, prognostic, and predictive biomarker of severe asthma
Tags
feno
MAT-GLB-2507044 - 1.0 - 12/2025

About this expert

Allergy/Immunology
Pulmonology

Miguel Lanz

MD, FAAAAI

Lanz Allergy, Asthma & Immunology AAADRS Clinical Research Center | Coral Gables, FL

See author’s profile
Miguel Lanz

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: KuwaitChange country/region